CHEK1 and neoplasm: AZD7762 is a CHK1/2 inhibitor that effectively reduced the proliferation and sphere-forming capacity of three breast cancer cell lines (4T1.2, MDA-MB-231, and MCF-7), which showed dose-dependent activity of tumor suppression and might be linked to enhanced apoptosis and autophagy in the 4T1.2 cell line [63].